Deerfield Management Company, L.P. (Series C) Biocryst Pharmaceuticals Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.76 Billion
- Q2 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 8,135,804 shares of BCRX stock, worth $64.9 Million. This represents 1.06% of its overall portfolio holdings.
Number of Shares
8,135,804
Previous 4,995,000
62.88%
Holding current value
$64.9 Million
Previous $25.4 Million
98.15%
% of portfolio
1.06%
Previous 0.52%
Shares
24 transactions
Others Institutions Holding BCRX
# of Institutions
258Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$159 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$150 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$100 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$74.6 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$70.4 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.48B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...